Page 3 - Imaging Phenomics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31st, 2021 Regulatory News: (excluding treasury shares**) (including treasury shares**) (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iB...

Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth 2020 results in line with expectations Acceleration of the growth dynamic in the first quarter of 2021 with revenue of €5.2m, an increase of 86% compared to Q1, 2020. Regulatory News: Median Technologies (Paris:ALMDT) (Euronext Growth ALMDT), whose Board of Directors met on April 6 th, 2021 to approve the consolidated financial statements for the financial year 2020, is today releasing its detailed audited full year financial results for ...

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares

(2) These two appointments follow a series of first successful achievements for iBiopsy in 2020 and early 2021. Median prepares to launch its iBiopsy product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy operations globally. Regulatory News: Thomas Bonnefont (Photo: Median Technologies) Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy Business Unit as well as the appointment of Mike Doherty as Sr. Stra...

(1) Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021. Regulatory News: Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations based on Low ...